Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
四川科倫博泰生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6990)

NOTICE OF EXTRAORDINARY GENERAL MEETING

NOTICE IS HEREBY GIVEN THAT the extraordinary general meeting (the "**EGM**") of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "**Company**") will be held at Meeting Room 1, 2/F, K1 Building, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., No. 666 Xinhua Avenue, Chengdu Cross-Strait Science and Technology Industry Development Park, Wenjiang District, Chengdu, Sichuan Province, the PRC at 9:00 a.m. on December 31, 2025 for the following purposes (unless otherwise indicated, capitalized terms used in this notice shall have the same meanings as those defined in the circular of the Company dated December 15, 2025 (the "**Circular**"):

ORDINARY RESOLUTIONS

For the Independent Shareholders to consider, and, if thought fit, pass the following resolutions:

1. "**THAT**

   (a) The 2026 Promotional Services Framework Agreement entered into between the Company and Kelun Jiaxun dated December 15, 2025, a copy of which is tabled at the meeting, the terms thereof and the transactions contemplated thereunder together with the proposed annual caps, be and are hereby approved, confirmed and ratified; and

(b) any one or more of the Directors be and are hereby authorised for and on behalf of the Company to sign, seal, execute, perfect, perform and deliver all such documents, instruments, deeds and agreements, to do all such acts, matters or things and take all such steps as he/she/they may in their discretion consider to be necessary, desirable, appropriate or expedient to give effect to and/or to implement the 2026 Promotional Services Framework Agreement and the transactions contemplated thereunder."

2. "**THAT**

(a) the 2026 Auxiliary R&D Services Framework Agreement entered into between the Company and Kelun Pharmaceutical dated December 15, 2025, a copy of which is tabled at the meeting, the terms thereof and the transactions contemplated thereunder together with the proposed annual caps, be and are hereby approved, confirmed and ratified; and

(b) any one or more of the Directors be and are hereby authorised for and on behalf of the Company to sign, seal, execute, perfect, perform and deliver all such documents, instruments, deeds and agreements, to do all such acts, matters or things and take all such steps as he/she/they may in their discretion consider to be necessary, desirable, appropriate or expedient to give effect to and/or to implement the 2026 Auxiliary R&D Services Framework Agreement and the transactions contemplated thereunder."

3. "**THAT**

(a) the 2026 Procurement and Sale of Equipment and Materials Framework Agreement entered into between the Company and Kelun Pharmaceutical dated December 15, 2025, a copy of which is tabled at the meeting, the terms thereof and the transactions contemplated thereunder together with the proposed annual caps, be and are hereby approved, confirmed and ratified; and

(b) any one or more of the Directors be and are hereby authorised for and on behalf of the Company to sign, seal, execute, perfect, perform and deliver all such documents, instruments, deeds and agreements, to do all such acts, matters or things and take all such steps as he/she/they may in their discretion consider to be necessary, desirable, appropriate or expedient to give effect to and/or to implement the 2026 Procurement and Sale of Equipment and Materials Framework Agreement and the transactions contemplated thereunder."

SPECIAL RESOLUTIONS

To consider and, if thought fit, pass the following resolutions as special resolutions:

1. "**THAT**:

   (a) subject to and conditional upon the Listing Committee of The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") granting the approval for the listing of, and permission to deal in, the Shares which may fall to be allotted and issued (and/or transferred out of treasury) pursuant to the vesting of the awards (the "**Share Awards**") that may be granted under the 2025 Share Incentive Scheme (the rules of which are contained in the document marked "A" produced to the EGM and initialed by the chairman of the EGM for the purpose of identification) (the "**2025 Share Incentive Scheme**"), the 2025 Share Incentive Scheme be and is hereby approved and adopted and the Directors and its Delegate(s) be and are hereby authorized to do all such acts and to enter into all such transactions, arrangements and agreements as may be necessary or expedient in order to give full effect to the 2025 Share Incentive Scheme including without limitation:

      (i) to administer the 2025 Share Incentive Scheme;

      (ii) to modify and/or amend the 2025 Share Incentive Scheme from time to time provided that such modification and/or amendment is effected in accordance with the provisions of the 2025 Share Incentive Scheme relating to modification and/or amendment and subject to Chapter 17 of the Listing Rules;

      (iii) to allot and issue from time to time such number of Shares as may be required to be allotted and issued and to procure the transfer of and deal with the Shares (including treasury shares, as the case may be) pursuant to the vesting of the Share Awards granted under the 2025 Share Incentive Scheme;

      (iv) to make application at the appropriate time or times to the Stock Exchange for the listing of, and permission to deal in any Shares (or transferred out of treasury) which may thereafter from time to time be allotted and issued pursuant to the vesting of the Share Awards granted under the 2025 Share Incentive Scheme; and

(v) to consent, if they deem fit and expedient, to such conditions, modifications and/or variations as may be required or imposed by the relevant authorities in relation to the 2025 Share Incentive Scheme."

2. "**THAT**:

the scheme mandate limit of the 2025 Share Incentive Scheme (being 3,500,000 H Shares) be and is hereby approved and adopted."

By order of the Board
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
LIU Gexin
Chairman of the Board and Non-executive Director

Hong Kong, December 15, 2025

Notes:

1. All resolutions at the EGM will be taken by poll (except where the chairman decides to allow a resolution relating to a procedural or administrative matter to be voted on by a show of hands) pursuant to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. The results of the poll will be published on the websites of the Company at https://kelun-biotech.com and Hong Kong Exchanges and Clearing Limited at www.hkexnews.hk after the EGM.

2. Any Shareholder entitled to attend and vote at the EGM convened by the above notice is entitled to appoint one or more proxies to attend and vote instead of him/her. A proxy need not be a Shareholder of the Company.

3. In order to be valid, the instrument appointing a proxy together with the power of attorney or other authority, if any, under which it is signed, or a notarially certified copy of such power of attorney or authority, must be completed and returned to the Company's H Share Registrar, Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong (for holders of H Shares), at least 24 hours before the EGM (i.e. before 9:00 a.m. on December 30, 2025) or any adjourned meeting thereof. Completion and return of the form of proxy will not preclude a Shareholder from attending and voting at the EGM or any adjourned meeting thereof should he/she so wish.

4. For the purpose of determining the list of Shareholders who are entitled to attend the EGM, the register of members of the Company will be closed from December 24, 2025 to December 31, 2025, both days inclusive, during which period no transfer of Shares will be registered. In order to be eligible to attend and vote at the EGM, unregistered Shareholders shall ensure all transfer documents accompanied by the relevant share certificates are lodged with the Company's H Share Registrar, Computershare Hong Kong Investor Services Limited at Shops 1712–1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong not later than 4:30 p.m. on December 23, 2025 for registration.

5. In the case of joint Shareholders, the vote of the senior joint Shareholder who tenders a vote, whether in person or by proxy, will be accepted to the exclusion of the vote(s) of the other joint Shareholder(s) and for this purpose, seniority will be determined by the order in which the names stand in the register of members of the Company in respect of the joint shareholding.

6. Shareholders who attend the EGM in person or by proxy shall bear their own travelling and accommodation expenses.

7. A Shareholder or his/her proxy should produce proof of identity when attending the EGM.

8. Contact information of the meeting:

   Contact person: Zhuo Chen
   Telephone: +86–18084866369
   Email: yfchengz@kelun.com
   Address: No. 666 Xinhua Avenue Chengdu Cross-Strait Science and Technology Industry Development Park Wenjiang District, Chengdu, Sichuan Province, PRC

9. Further details of the resolutions are set out in the circular of the Company dated December 15, 2025. Unless otherwise indicated, capitalized terms used in this notice shall have the same meanings as those defined in the circular.

10. References to dates and time in this notice are to Hong Kong dates and time.

11. The English text of this notice shall prevail over the Chinese text for the purpose of interpretation.

12. References herein to an allotment, issue or dealing with securities or shares shall include a sale or transfer of treasury shares listed on the Stock Exchange.

As at the date of this notice, the Board comprises Mr. LIU Gexin as the chairman of the Board and non-executive Director, Dr. GE Junyou as executive Director, Mr. LIU Sichuan, Mr. LAI Degui, Mr. FENG Hao, Ms. LIAO Yihong and Mr. ZENG Xuebo as non-executive Directors, and Dr. ZHENG Qiang, Dr. TU Wenwei, Dr. JIN Jinping, and Dr. LI Yuedong as independent non-executive Directors.